Targeted therapies for CLL: Practical issues with the changing treatment paradigm

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chemoimmunotherapy (CIT), exemplified by FCR (fludarabine, cyclophosphamide, rituximab), has been the established first-line treatment for younger chronic lymphocytic leukemia (CLL) patients.
• Recent advancements have introduced novel targeted therapies for CLL management.

Purpose of the Study:

• To review the landscape of novel targeted therapies for chronic lymphocytic leukemia (CLL).
• To highlight emerging treatment strategies and their potential impact on CLL care.

Main Methods:

• Review of recently developed targeted therapies for CLL.
• Categorization of novel agents based on their mechanisms of action (e.g., BCR inhibitors, Bcl-2 antagonists, immune-targeting strategies).
• Mention of approved drugs and ongoing clinical trials.

Main Results:

• Several novel targeted therapies are available for CLL, including Bruton tyrosine kinase (BTK) inhibitors, PI3 kinase inhibitors, Syk inhibitors, novel anti-CD20 monoclonal antibodies (ofatumumab, obinutuzumab), and Bcl-2 antagonists (venetoclax).
• Ibrutinib and idelalisib are approved for relapsed/refractory CLL, with ibrutinib also indicated for first-line treatment in del(17p) CLL.
• Immune-targeting strategies like lenalidomide, CAR T cells, and checkpoint inhibitors are in clinical development.

Conclusions:

• Novel targeted therapies are transforming CLL treatment, offering new options beyond traditional chemoimmunotherapy.
• Ongoing phase III trials are crucial for defining the definitive role of these targeted agents in CLL management.
• The evolving therapeutic landscape promises improved outcomes for CLL patients.